-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse Börse FrankfurtEURSymbol 2VB-
Provention BioBörse Börse FrankfurtEURSymbol 2VB
-
Provention BioBörse Börse BerlinSymbol 2VB
-
Provention BioBörse Börse StuttgartEURSymbol 2VB
-
Provention BioBörse Gettex System der Börse MünchenEURSymbol 2VB
-
PROVENTION BIO INCBörse Börse HamburgEURSymbol 2VB
-
ISIN US74374N1028 WKN: A2JRLWSymbol PRVB
-
EUR
-
Symbol 2VB
-
Symbol 2VB
Währung
EUR
Börse
Börse Frankfurt Zeitzone: Europe/Berlin
Firmenname
Provention Bio, Inc
Marktkapitalisierung
797.583.680 (+- 17%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
934.167.360 oder 661.000.000
Mitarbeiter
97 (+- 80%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
19 oder 174 Mitarbeiter
EBITDA 0
PEGRatio None
Buchwert 2.397
Provention Bio outperformed den DAX um +23 % vom 30.07.2018 bis 14.07.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 11,61 USD -5,99%
5 ETFs die in Provention Bio investieren
Dir gefallen die Informationen zu Provention Bio?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Provention Bio?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Provention Bio?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Provention Bio?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
39 News & Informationen zur Provention Bio Aktie
Provention Bio, Inc. 2021 Q2 – Results – Earnings Call Presentation (NASDAQ:PRVB)
The following slide deck was published by Provention Bio, Inc.
Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 9.80% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Provention Bio EPS beats by $0.06 (NASDAQ:PRVB)
Provention Bio (PRVB): Q2 GAAP EPS of -$0.46 beats by $0.06.Cash and cash equivalents and marketable securities of $176.4 million.Press Release
Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
/PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today…
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of …
Provention Bio: Blood (Glucose) In The Streets (NASDAQ:PRVB)
It's been almost 18 months since I posted a comprehensive clinical overview of Provention Bio's main molecule teplizumab.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline – PRVB
NEW YORK, July 18, 2021 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. and certain of its officers. The class… | July 18, 2021
Glancy Prongay & Murray LLP Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
LOS ANGELES, July 15, 2021 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 20, 2021 deadline to file a lead
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
/PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the class…
DEADLINE ALERT for PRVB, WPG, SPCE, OCGN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
BENSALEM, Pa., July 15, 2021 — Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded…
Teplizumab Awarded Innovation Passport in the United Kingdom (UK) for the Delay of Onset of Clinical Type 1 Diabetes in At-risk Individuals
/PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today…
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, In…
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
Investors with losses exceeding $100,000 are encouraged to contact the firm LOS ANGELES, July 08, 2021 — Glancy Prongay & Murray LLP reminds investors of the upcoming July 20,…
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Provention Bio, Washington Prime, Virgin Galactic, and RLX and Encourages Investors to Contact the Firm
NEW YORK, July 07, 2021 — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of…
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ju…
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.60% By Investing.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.60%
Mid-Afternoon Market Update: Dow Tumbles 300 Points; Advaxis Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.86% to 34,488.53 while the NASDAQ fell 0.08% to 14,626.98. The S&P also fell, dropping 0.48% to …
Here's Why Provention Bio Stock Is Diving Today
The company's latest letter from the FDA wasn't what investors had hoped for.
Provention Bio : Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals (Form 8-K)
Provention Bio Receives Complete Response Letter to Biologics License Application for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-risk Individuals
Previously… | July 6, 2021
ROSEN, A TOP RANKED LAW FIRM, Encourages Provention Bio, Inc. Investors With Losses to Secure Counsel Before Important July 20 Deadline in Securities Class Action – PRVB
NEW YORK, July 05, 2021 — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. between November 2, 2020 and April 8, 2021,…
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (…
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors
/PRNewswire/ — The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or…
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
Investors with losses exceeding $100,000 are encouraged to contact the firm…
Hedge Funds Are Buying Zepp Health Corporation (ZEPP)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Provention Bio, Inc. – PRVB
NEW YORK, April 13, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Provention Bio, Inc. . Such investors are advised to contact… | April 14, 2021
Are Biotech Penny Stocks Worth It?
Biotech penny stocks can be an interesting addition to your investment portfolio and many investors are bringing in massive gains.
Are Options Traders Betting on a Big Move in Provention Bio (PRVB) Stock?
Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
Beyond Celiac Celebrates Record Accomplishments in 2020
Philadelphia, PA, Jan. 14, 2021 — Beyond Celiac, the leading catalyst for a celiac disease cure in the United States, partnered with a record number of key biotechnology and pharmaceutical…
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.02% By Investing.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.02%
Mid-Afternoon Market Update: Dow Rises 75 Points; Motorsport Games Shares Spike Higher
Toward the end of trading Wednesday, the Dow traded up 0.24% to 31,143.93 while the NASDAQ rose 0.73% to 13,168.19. The S&P also rose, gaining…
Mid-Afternoon Market Update: Dow Rises 75 Points; Motorsport Games Shares Spike Higher
Toward the end of trading Wednesday, the Dow traded up 0.24% to 31,143.93 while the NASDAQ rose 0.73% to 13,168.19. The S&P also rose, gaining 0.5% to …
Stocks of Note for Jan-13 Morning
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 12) …
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Biolase (NASDAQ:BIOL) stock rose 22.11% to $1.27 during Tuesday's after-market session. At the close, Biolase's trading volume reached 14.5 …
Provention Bio -5.9% AH as company announces public offering (NASDAQ:PRVB)
Provention Bio Announces Proposed Public Offering of Common Stock
/PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today…
Is the Options Market Predicting a Spike in Provention Bio (PRVB) Stock?
Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
CALA Falls As CANTATA Trial Fails, Haven Healthcare To Be Disbanded, MTNB Awaits MAT9001 Data In Q1
Today’s Daily Dose brings you news about Pandion’s phase Ia trial of autoimmune disease drug PT101 in healthy volunteers; Matinas BioPharma’s anticipated milestone for this quarter; Calithera’s disappointing results from phase II study of Telaglenastat in patients with renal cell carcinoma, Provention Bio’s near-term regulatory catalyst; and disbanding of Haven Healthcare joint venture.
CALA Falls As CANTATA Trial Fails, Haven Healthcare To Be Disbanded, MTNB Awaits MAT9001 Data In Q1
(RTTNews) – Today’s Daily Dose brings you news about Pandion’s phase Ia trial of autoimmune disease drug PT101 in healthy volunteers; Matinas BioP…